Search Results - "Kuriakose, Emil T"

JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug by Kuriakose, Emil T, Gjoni, Stefani, Wang, Y Lynn, Baumann, Ruth, Jones, Amy V, Cross, Nicholas C P, Silver, Richard T

Get full text

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices by Jagannath, Sundar, Roy, Anuja, Kish, Jonathan, Lunacsek, Orsolya, Globe, Denise, Eaddy, Michael, Kuriakose, Emil T, Willey, Joanne, Butler-Bird, Stephanie, Siegel, David

“…Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Using…”
Get more information

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework by Roy, Anuja, Kish, Jonathan K, Bloudek, Lisa, Siegel, David S, Jagannath, Sundar, Globe, Denise, Kuriakose, Emil T, Migliaccio-Walle, Kristen

“…Multiple myeloma is a progressive cancer for which there is no cure. Despite treatment, almost all patients eventually experience periods of disease relapse…”
Get full text

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model by Bloudek, Lisa, Roy, Anuja, Kish, Jonathan K, Siegel, David S, Jagannath, Sundar, Globe, Denise, Orloski, Laurie, Kuriakose, Emil T

“…Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed…”
Get full text

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma by Hansen, Vincent L., Coleman, Morton, Elkins, Stephanie, Letzer, Jeffrey P., Levy, Moshe Yair, Seneviratne, Lasika, Rine, Jessica, White, Marina, Kuriakose, Emil T.

“…The panobinostat expansion (PANEX) treatment protocol (n = 39) provided access to panobinostat and gathered additional efficacy and safety data on the…”
Get full text

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study by Karmali, Reem, Landsburg, Daniel J., Westin, Jason, Leonard, John P., Kuriakose, Emil T., Sumrow, Bradley James, Carroll, Susheela, Albert, Katherine, Akella, Lalith, Gordon, Leo I.

Get full text

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma by Yang, Hongbo, Roy, Anuja, Yang, Chelsey, McDonald, Evangeline, Krishna, Arun, Kuriakose, Emil T, Globe, Denise, Siegel, David, Jagannath, Sundar

“…Background: Almost all patients with multiple myeloma will eventually become relapsed/refractory (RRMM). Current treatments for RRMM are mainly targeted…”
Get full text

Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model by Meille, Christophe, Guerreiro, Nelson, Jullion, Astrid, Bauer, Sebastian, Chatterjee, Manik, Vos, Filip de, Lin, Chia-Chi, Rodríguez, Cristina Suárez, Tai, David, Cassier, Philippe, Yamamoto, Noboru, Weger, Vincent A. de, Klopfenstein, Matthieu, Mariconti, Luisa, Kuriakose, Emil T., Hyman, David M.

“…Background: NVP-HDM201 is a selective inhibitor of the p53-HDM2 interaction, demonstrating potent preclinical activity, and is currently in Phase I clinical…”
Get full text

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias by Stein, Eytan, Chromik, Joerg, DeAngelo, Daniel J., Chatterjee, Manik, Noppeney, Richard, Vos, Filip de, Minami, Hironobu, Jeay, Sébastien, Meille, Christophe, Halilovic, Ensar, Mariconti, Luisa, Klopfenstein, Matthieu, Guerreiro, Nelson, Radhakrishnan, Rajkumar, Kuriakose, Emil T., Carpio, Cecilia

“…Background: NVP-HDM201 is a selective inhibitor of the p53-HDM2 interaction and has demonstrated potent single-agent activity in various in vitro and in vivo…”
Get full text

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma by Hansen, Vincent L, Coleman, Morton, Elkins, Stephanie, Letzer, Jeffrey P., Levy, Moshe Yair, Seneviratne, Lasika, Rine, Jessica, White, Marina, Kuriakose, Emil T

“…Introduction: Panobinostat (PAN) is a potent pan-deacetylase inhibitor that targets multiple myeloma (MM) cells via its effects on epigenetics and protein…”
Get full text

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs by Jagannath, Sundar, Roy, Anuja, Kish, Jonathan K, Globe, Denise, Lunacsek, Orsolya, Eaddy, Michael T., Kuriakose, Emil T, Willey, Joanne, Siegel, David

“…Background: There are limited data on real-world treatment outcomes for novel agents used in the treatment of relapsed/refractory multiple myeloma (RRMM)…”
Get full text

Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with TP53 wt advanced tumors by Hyman, David M., Chatterjee, Manik, Vos, Filip de, Lin, Chia-Chi, Suárez, Cristina, Tai, David, Cassier, Philippe, Yamamoto, Noboru, Weger, Vincent A. de, Jeay, Sébastien, Meille, Christophe, Halilovic, Ensar, Mariconti, Luisa, Klopfenstein, Matthieu, Guerreiro, Nelson, Radhakrishnan, Rajkumar, Kuriakose, Emil T., Bauer, Sebastian

“…Background: NVP-HDM201 is a selective inhibitor of the p53-HDM2 interaction, and has demonstrated potent single-agent activity in various in vitro and in vivo…”
Get full text